$ 0.88
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.
Target Price
The average target price of STRO is 2.9 and suggests 226% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
